pregabalin + pregabalin/PF-00489791 + Placebo

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Postherpetic Neuralgia

Conditions

Postherpetic Neuralgia

Trial Timeline

Apr 9, 2008 → Dec 23, 2008

About pregabalin + pregabalin/PF-00489791 + Placebo

pregabalin + pregabalin/PF-00489791 + Placebo is a phase 2 stage product being developed by Pfizer for Postherpetic Neuralgia. The current trial status is completed. This product is registered under clinical trial identifier NCT00599638. Target conditions include Postherpetic Neuralgia.

What happened to similar drugs?

4 of 8 similar drugs in Postherpetic Neuralgia were approved

Approved (4) Terminated (1) Active (4)

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00599638Phase 2Completed

Competing Products

20 competing products in Postherpetic Neuralgia

See all competitors
ProductCompanyStageHype Score
QUTENZAAstellas PharmaApproved
43
KHK6188 + PlaceboKyowa KirinPhase 2
35
ONO-1110 + PlaceboOno PharmaceuticalPhase 2
39
Placebo + Pregabalin SR tablet 165mg/day + Pregabalin SR tablet 330mg/day + Pregabalin SR tablet 660mg/dayJiangsu Hengrui MedicinePhase 3
36
MK-8291 + PlaceboMerckPhase 1
29
Etoricoxib + PlaceboMerckApproved
39
ADL5747 + Placebo + PregabalinMerckPhase 2
27
MK0759MerckPhase 2
27
MK0686MerckPhase 2
27
Comparator: pregabalin + Comparator: Placebo (unspecified)MerckPhase 1
29
Lyrica (pregabalin) + PlaceboPfizerApproved
43
RN624 + RN624 + PlaceboPfizerPhase 2
35
T-62PfizerPhase 2
27
PH-797804 + PlaceboPfizerPhase 2
35
Placebo + Pregabalin + Pregabalin + PregabalinPfizerPhase 3
40
pregabalinPfizerPhase 3
40
pregabalinPfizerApproved
35
T-62 Dose 1 + T-62 Dose 2PfizerPhase 2
27
HSK16149 20mg BID + HSK16149 40mg BID + Placebo BIDHaisco Pharmaceutical GroupPhase 3
40
LevetiracetamUCBPhase 2
35